Fresenius Medical Care: Margin Expansion Supports The Story, But Growth Remains Limited
Fresenius Medical Care is improving operationally, with Q2 2026 organic revenue up 5% and adjusted operating profit up 23%.
Model output · Signal date 2026-10-14
Fresenius Medical Care Ag (FMS) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Rating · 90D
▼ Bearish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Bottom 35%
of 5379 stocks scored
Rank correlation · 90D
n/a
No per-ticker sample yet
Market Cap
$5.89B
mid-cap · #2 of 11 peers
Summary
Fresenius Medical Care Ag (FMS) stock forecast summary
Our AI ranks Fresenius Medical Care Ag outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Fresenius Medical Care Ag is a mid-cap company with a market capitalization of $5.89B. It ranks number 2 by market capitalization among the 11 Services-Misc Health & Allied Services, NEC issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for FMS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, FMS included.
Follow FMS freePrice
FMS price chart and AI forecast
Cross-section · 2026-10-13
How FMS ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals
Fresenius Medical Care Ag (FMS) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Misc Health & Allied Services, NEC peers listed below that report each metric.
Valuation & Market
| Metric | FMS | Rank |
|---|---|---|
| Market Cap | $5.89B | 2/11 |
| EPS | $4.06 | – |
Profitability & Margins
| Metric | FMS | Rank |
|---|---|---|
| Tax Rate | 31.5% | – |
Financial Health
| Metric | FMS | Rank |
|---|---|---|
| Interest Coverage | 7.4x | 4/12 |
Cash Flow
| Metric | FMS | Rank |
|---|---|---|
| Operating Cash Flow | $2.14B | 2/11 |
| OCF Growth YoY | 9.2% | 4/7 |
Income Statement
| Metric | FMS | Rank |
|---|---|---|
| Operating Income | $2.64B | 1/10 |
| R&D Expense | $162M | 1/6 |
| SG&A Expense | $3.04B | 1/6 |
| Cost of Goods Sold | $1.47B | 1/8 |
Dividend & Shareholder Information
| Metric | FMS | Rank |
|---|---|---|
| Shares Outstanding | 279M | – |
Quarterly Financial Reports
FMS quarterly financials and insider trading
Industry Peers · Services-Misc Health & Allied Services, NEC
Fresenius Medical Care Ag (FMS) industry peers
Companies classified under the same SEC industry code as Fresenius Medical Care Ag (Services-Misc Health & Allied Services, NEC): 13 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| FMS Fresenius Medical Care Ag | ▼ | $5.89B |
| DVA Davita Inc. | ▶ | $11.62B |
| SHC Sotera Health Co | ▼ | $5.20B |
| PGNY Progyny, Inc. | ▶ | $2.10B |
| AGL Agilon Health, Inc. | ▶ | $1.44B |
| VMD Viemed Healthcare, Inc. | ▲ | $366M |
| PARK Park Dental Partners, Inc. | ▲ | $96M |
| MRAI Marpai, Inc. | ▲ | $87M |
| CCEL Cryo Cell International Inc | ▲ | $36M |
| PFHO Pacific Health Care Organization Inc | ▲ | $12M |
| MGRX Mangoceuticals, Inc. | ▶ | $8M |
| BRTX Biorestorative Therapies, Inc. | ▶ | N/A |
| NIVF Newgenivf Group Ltd | ▼ | N/A |
Where FMS sits on the market map
Industrial Applications and Services · Services-Misc Health & Allied Services, NEC
News
Fresenius Medical Care Ag (FMS) stock news
Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth
Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, ...
Fresenius Medical Care named Korangy CEO. FMC stock gains 1.40 percent
Revenue rose 1.40 percent to EUR 4.86 billion in the second quarter. FMC stock costs EUR 38.43 on October 13, 2026 versus EUR ...
FAQ
Fresenius Medical Care Ag (FMS) stock forecast FAQ
What is the Fresenius Medical Care Ag (FMS) stock forecast?
Our AI ranks Fresenius Medical Care Ag outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Fresenius Medical Care Ag stock predictions?
A per-ticker accuracy statistic for FMS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Fresenius Medical Care Ag forecasts updated?
Fresenius Medical Care Ag forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Fresenius Medical Care Ag's industry peers?
13 issuers in our coverage, FMS included, share the SEC industry code Services-Misc Health & Allied Services, NEC. The largest are: Davita Inc. (DVA), Sotera Health Co (SHC), Progyny, Inc. (PGNY), Agilon Health, Inc. (AGL), Viemed Healthcare, Inc. (VMD), Park Dental Partners, Inc. (PARK).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.